

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-59 (canceled)

Claim 60 (currently amended): A method for inhibiting $\alpha_v\beta_5$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_5$ antagonist, wherein said antagonist is a matrix metalloproteinase polypeptide consisting of: ~~that includes an amino acid sequence shown in~~ SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

Claims 61-64 (canceled)

Claim 65 (previously presented): The method of claim 60 wherein said tissue is human tissue.

Claim 66 (previously presented): The method of claim 65 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

Claim 67 (previously presented): The method of claim 60 wherein said tissue is arthritic.

Claim 68 (previously presented): The method of claim 67 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim 69 (previously presented): The method of claim 60 wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim 70 (previously presented): The method of claim 69 wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim 71 (previously presented): The method of claim 60 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim 72 (previously presented): The method of claim 71 wherein said tissue is a carcinoma.

Claim 73 (previously presented): The method of claim 71 wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim 74 (previously presented): The method of claim 71 wherein said administering is conducted in conjunction with chemotherapy.

Claim 75 (previously presented): The method of claim 60 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 76 (previously presented): The method of claim 60 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 77 (previously presented): The method of claim 60 wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 78 (previously presented): The method of claim 60 wherein said administering comprises a single dose intravenously.

Claim 79 (previously presented): The method of claim 60 wherein said administering comprises one or more dose administrations daily for one or more days.

Claim 80 (previously presented): The method of claim 60 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

Claim 81 (previously presented): The method of claim 60 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.




Claim 82 (previously presented): The method of claim 60 wherein said angiogenesis is induced by a cytokine.



Claim 83 (previously presented): The method of claim 82 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- α and epidermal growth factor.

Claim 84 (previously presented): The method of claim 82 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.

Claims 85-87 (canceled)

Claim 88 (currently amended): A method for inhibiting $\alpha_v\beta_5$ mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_5$ antagonist, wherein said antagonist is an organic compound selected from the group consisting of compounds ~~7, 9, 10, 12, AND 14.~~ represented by the following structures:





Claim 89 (previously presented): The method of claim 88 wherein said tissue is human tissue.

Claim 90 (previously presented): The method of claim 89 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

Claim 91 (previously presented): The method of claim 88 wherein said tissue is arthritic.

Claim 92 (previously presented): The method of claim 91 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim 93 (previously presented): The method of claim 88 wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim 94 (previously presented): The method of claim 93 wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim 95 (previously presented): The method of claim 88 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim 96 (previously presented): The method of claim 95 wherein said tissue is a carcinoma.

Claim 97 (previously presented): The method of claim 95 wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim 98 (previously presented): The method of claim 95 wherein said administering is conducted in conjunction with chemotherapy.

Claim 99 (previously presented): The method of claim 88 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 100 (previously presented): The method of claim 88 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 101 (previously presented): The method of claim 88 wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 102 (previously presented): The method of claim 88 wherein said administering comprises a single dose intravenously.

Claim 103 (previously presented): The method of claim 88 wherein said administering comprises one or more dose administrations daily for one or more days.

Claim 104 (previously presented): The method of claim 88 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

Claim 105 (previously presented): The method of claim 88 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

Claim 106 (previously presented): The method of claim 88 wherein said angiogenesis is induced by a cytokine.

Claim 107 (previously presented): The method of claim 106 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- α and epidermal growth factor.

Claim 108 (previously presented): The method of claim 106 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.